Heterologous Systemic Prime–Intranasal Boosting Using a Spore SARS-CoV-2 Vaccine Confers Mucosal Immunity and Cross-Reactive Antibodies in Mice as well as Protection in Hamsters

Background: Current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are administered systemically and typically result in poor immunogenicity at the mucosa. As a result, vaccination is unable to reduce viral shedding and transmission, ultimately failing to prevent infection. On...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsande, Paidamoyo M., Fernández-Bastit, Leira, Ferreira, William T., Vergara-Alert, Júlia, Hess, Mateusz, Lloyd-Jones, Katie, Hong, Huynh A., Segales, Joaquim, Cutting, Simon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692796/
https://www.ncbi.nlm.nih.gov/pubmed/36366408
http://dx.doi.org/10.3390/vaccines10111900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692796/
https://www.ncbi.nlm.nih.gov/pubmed/36366408
http://dx.doi.org/10.3390/vaccines10111900

Ejemplares similares